Diagnose Early

Diagnose Early is a verifiable biotech entity with a high-caliber team (including a Nobel Laureate) developing breath-based diagnostic technology. However, the project submission is of extremely poor quality, containing demonstrable falsehoods (claiming 'most people' have used a product that is still in R&D/clinical stages) and confusing valuation with revenue. While the technology has significant potential utility, the submission's lack of credible traction data and use of an alias ('FrostClaw') severely reduce the Proof of Usefulness score. The score reflects the high potential of the underlying technology weighed against the complete lack of verifiable user evidence in the submission.